These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 32882100)

  • 1. A Phase 1 Randomized Trial of Specific Active α-Synuclein Immunotherapies PD01A and PD03A in Multiple System Atrophy.
    Meissner WG; Traon AP; Foubert-Samier A; Galabova G; Galitzky M; Kutzelnigg A; Laurens B; Lührs P; Medori R; Péran P; Sabatini U; Vergnet S; Volc D; Poewe W; Schneeberger A; Staffler G; Rascol O;
    Mov Disord; 2020 Nov; 35(11):1957-1965. PubMed ID: 32882100
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and immunogenicity of the α-synuclein active immunotherapeutic PD01A in patients with Parkinson's disease: a randomised, single-blinded, phase 1 trial.
    Volc D; Poewe W; Kutzelnigg A; Lührs P; Thun-Hohenstein C; Schneeberger A; Galabova G; Majbour N; Vaikath N; El-Agnaf O; Winter D; Mihailovska E; Mairhofer A; Schwenke C; Staffler G; Medori R
    Lancet Neurol; 2020 Jul; 19(7):591-600. PubMed ID: 32562684
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and Tolerability of Active Immunotherapy Targeting α-Synuclein with PD03A in Patients with Early Parkinson's Disease: A Randomized, Placebo-Controlled, Phase 1 Study.
    Poewe W; Volc D; Seppi K; Medori R; Lührs P; Kutzelnigg A; Djamshidian A; Thun-Hohenstein C; Meissner WG; Rascol O; Schneeberger A; Staffler G; ; ; Poewe W; Seppi K; Djamshidian A; deMarzi R; Heim B; Mangesius S; Stolz R; Wachowicz K; Volc D; Thun-Hohenstein C; Riha C; Schneeberger A; Bürger V; Galabova G
    J Parkinsons Dis; 2021; 11(3):1079-1089. PubMed ID: 34092654
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Randomized First-in-Human Study With UB-312, a UBITh® α-Synuclein Peptide Vaccine.
    Yu HJ; Thijssen E; van Brummelen E; van der Plas JL; Radanovic I; Moerland M; Hsieh E; Groeneveld GJ; Dodart JC
    Mov Disord; 2022 Jul; 37(7):1416-1424. PubMed ID: 35426173
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and Tolerability of Multiple Ascending Doses of PRX002/RG7935, an Anti-α-Synuclein Monoclonal Antibody, in Patients With Parkinson Disease: A Randomized Clinical Trial.
    Jankovic J; Goodman I; Safirstein B; Marmon TK; Schenk DB; Koller M; Zago W; Ness DK; Griffith SG; Grundman M; Soto J; Ostrowitzki S; Boess FG; Martin-Facklam M; Quinn JF; Isaacson SH; Omidvar O; Ellenbogen A; Kinney GG
    JAMA Neurol; 2018 Oct; 75(10):1206-1214. PubMed ID: 29913017
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anle138b modulates α-synuclein oligomerization and prevents motor decline and neurodegeneration in a mouse model of multiple system atrophy.
    Heras-Garvin A; Weckbecker D; Ryazanov S; Leonov A; Griesinger C; Giese A; Wenning GK; Stefanova N
    Mov Disord; 2019 Feb; 34(2):255-263. PubMed ID: 30452793
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ATH434 Reduces α-Synuclein-Related Neurodegeneration in a Murine Model of Multiple System Atrophy.
    Heras-Garvin A; Refolo V; Schmidt C; Malfertheiner K; Wenning GK; Bradbury M; Stamler D; Stefanova N
    Mov Disord; 2021 Nov; 36(11):2605-2614. PubMed ID: 34236731
    [TBL] [Abstract][Full Text] [Related]  

  • 8. mTOR Inhibition with Sirolimus in Multiple System Atrophy: A Randomized, Double-Blind, Placebo-Controlled Futility Trial and 1-Year Biomarker Longitudinal Analysis.
    Palma JA; Martinez J; Millar Vernetti P; Ma T; Perez MA; Zhong J; Qian Y; Dutta S; Maina KN; Siddique I; Bitan G; Ades-Aron B; Shepherd TM; Kang UJ; Kaufmann H
    Mov Disord; 2022 Apr; 37(4):778-789. PubMed ID: 35040506
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized Phase I Trial of the α-Synuclein Antibody Lu AF82422.
    Buur L; Wiedemann J; Larsen F; Ben Alaya-Fourati F; Kallunki P; Ditlevsen DK; Sørensen MH; Meulien D
    Mov Disord; 2024 Jun; 39(6):936-944. PubMed ID: 38494847
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase 1/1b Studies of UCB0599, an Oral Inhibitor of α-Synuclein Misfolding, Including a Randomized Study in Parkinson's Disease.
    Smit JW; Basile P; Prato MK; Detalle L; Mathy FX; Schmidt A; Lalla M; Germani M; Domange C; Biere AL; Bani M; Carson S; Genius J
    Mov Disord; 2022 Oct; 37(10):2045-2056. PubMed ID: 35959805
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nilotinib Fails to Prevent Synucleinopathy and Cell Loss in a Mouse Model of Multiple System Atrophy.
    Lopez-Cuina M; Guerin PA; Canron MH; Delamarre A; Dehay B; Bezard E; Meissner WG; Fernagut PO
    Mov Disord; 2020 Jul; 35(7):1163-1172. PubMed ID: 32291831
    [TBL] [Abstract][Full Text] [Related]  

  • 12. α-Synuclein-induced myelination deficit defines a novel interventional target for multiple system atrophy.
    Ettle B; Kerman BE; Valera E; Gillmann C; Schlachetzki JC; Reiprich S; Büttner C; Ekici AB; Reis A; Wegner M; Bäuerle T; Riemenschneider MJ; Masliah E; Gage FH; Winkler J
    Acta Neuropathol; 2016 Jul; 132(1):59-75. PubMed ID: 27059609
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized phase I clinical trial of anti-α-synuclein antibody BIIB054.
    Brys M; Fanning L; Hung S; Ellenbogen A; Penner N; Yang M; Welch M; Koenig E; David E; Fox T; Makh S; Aldred J; Goodman I; Pepinsky B; Liu Y; Graham D; Weihofen A; Cedarbaum JM
    Mov Disord; 2019 Aug; 34(8):1154-1163. PubMed ID: 31211448
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Altered α-synuclein, parkin, and synphilin isoform levels in multiple system atrophy brains.
    Brudek T; Winge K; Rasmussen NB; Bahl JM; Tanassi J; Agander TK; Hyde TM; Pakkenberg B
    J Neurochem; 2016 Jan; 136(1):172-85. PubMed ID: 26465922
    [TBL] [Abstract][Full Text] [Related]  

  • 15. First-in-human assessment of PRX002, an anti-α-synuclein monoclonal antibody, in healthy volunteers.
    Schenk DB; Koller M; Ness DK; Griffith SG; Grundman M; Zago W; Soto J; Atiee G; Ostrowitzki S; Kinney GG
    Mov Disord; 2017 Feb; 32(2):211-218. PubMed ID: 27886407
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The molecular tweezer CLR01 reduces aggregated, pathologic, and seeding-competent α-synuclein in experimental multiple system atrophy.
    Herrera-Vaquero M; Bouquio D; Kallab M; Biggs K; Nair G; Ochoa J; Heras-Garvin A; Heid C; Hadrovic I; Poewe W; Wenning GK; Klärner FG; Schrader T; Bitan G; Stefanova N
    Biochim Biophys Acta Mol Basis Dis; 2019 Nov; 1865(11):165513. PubMed ID: 31319154
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Insulin resistance and exendin-4 treatment for multiple system atrophy.
    Bassil F; Canron MH; Vital A; Bezard E; Li Y; Greig NH; Gulyani S; Kapogiannis D; Fernagut PO; Meissner WG
    Brain; 2017 May; 140(5):1420-1436. PubMed ID: 28334990
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Viral-mediated oligodendroglial alpha-synuclein expression models multiple system atrophy.
    Bassil F; Guerin PA; Dutheil N; Li Q; Klugmann M; Meissner WG; Bezard E; Fernagut PO
    Mov Disord; 2017 Aug; 32(8):1230-1239. PubMed ID: 28556404
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Distinct Autoimmune Anti-α-Synuclein Antibody Patterns in Multiple System Atrophy and Parkinson's Disease.
    Folke J; Rydbirk R; Løkkegaard A; Salvesen L; Hejl AM; Starhof C; Bech S; Winge K; Christensen S; Pedersen LØ; Aznar S; Pakkenberg B; Brudek T
    Front Immunol; 2019; 10():2253. PubMed ID: 31616427
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Who Ever Said It Would Be Easy? Reflecting on Two Clinical Trials Targeting α-Synuclein.
    Jensen PH; Schlossmacher MG; Stefanis L
    Mov Disord; 2023 Mar; 38(3):378-384. PubMed ID: 36645106
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.